(Q51406750)

English

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

scientific article published in November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Jorgen K. Kanters

7

object named as

Jørgen K Kanters

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

author name string

Jørgen Matz

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Petri J Vainio

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Antero Kallio

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Astrid Maria Højer

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Johannes J Struijk

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Mads P Andersen

8

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Egon Toft

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

publication date

1 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

31

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

11

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

799-811

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

In vivo characterization of the opioid antagonist nalmefene in mice

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Thorough QT Studies: Questions and Quandaries

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Quantitative analysis of T-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35-138.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Reference values of electrocardiogram repolarization variables in a healthy population.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Sertindole causes distinct electrocardiographic T-wave morphology changes

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

New descriptors of T-wave morphology are independent of heart rate.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

T wave morphology analysis distinguishes between KvLQT1 and HERG mutations in long QT syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Evaluation of the Effects of AZD3480 on Cardiac Repolarization: A Thorough QT/QTc Study Using Moxifloxacin as a Positive Control

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Statistical characteristics of moxifloxacin-induced QTc effect

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

The effect of moxifloxacin on QTc and implications for the design of thorough QT studies

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Effects of liver disease on the disposition of the opioid antagonist nalmefene

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling

1 reference

https://api.crossref.org/works/10.1007%2FBF03256919

21 January 2018

Thorough QT study of the effect of fesoterodine on cardiac repolarization

1 reference

https://pubmed.ncbi.nlm.nih.gov/21967071

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21967071

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21967071

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene

1 reference

https://pubmed.ncbi.nlm.nih.gov/21967071

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF03256919

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21967071

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51406750&oldid=2079570100"